Myriad Genetics (MYGN) Aperçu de l'action
Myriad Genetics, Inc. est une entreprise de diagnostic moléculaire et de médecine de précision qui développe des tests moléculaires. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
MYGN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Myriad Genetics, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$2.86 |
| Plus haut sur 52 semaines | US$8.59 |
| Plus bas sur 52 semaines | US$2.81 |
| Bêta | 1.65 |
| Variation sur 1 mois | -52.33% |
| Variation sur 3 mois | -40.42% |
| Variation sur 1 an | -26.85% |
| Variation sur 3 ans | -85.19% |
| Variation sur 5 ans | -91.70% |
| Évolution depuis l'introduction en bourse | -46.79% |
Nouvelles et mises à jour récentes
Seeking Alpha • 6h
Myriad Genetics: Strong Oncology Demand, But Monetization Breaks Down
Summary Myriad Genetics faces persistent reimbursement and pricing headwinds, despite stable oncology volumes and pipeline momentum, driving margin compression and revenue volatility. Management is executing the Ascend initiative, aiming to optimize the revenue cycle, automate claims, and improve payer engagement, with the potential for margin inflection by 2027 if successful. FY26 revenue guidance is tightened to $770–$790 million, with adjusted EBITDA guidance withdrawn, reflecting near-term uncertainty and limited visibility on operational improvements. I maintain a Hold rating, as the business remains a turnaround story; execution on reimbursement and revenue conversion is critical before upside can be realized. Read the full article on Seeking Alpha
Mise à jour du récit • Jul 09
MYGN: New Cancer Test Data And AI Initiatives Will Support A Balanced Outlook
Analysts trimmed their price outlook for Myriad Genetics, lowering the implied fair value estimate from $8.12 to $6.25 as they recalibrated assumptions around revenue growth, profit margins, and future P/E expectations following recent research updates. What’s in the News for Myriad Genetics Myriad Genetics reported new large scale meta analysis data for its Prolaris Biopsy Test in localized prostate cancer, showing that the combined clinical risk score was significantly prognostic for distant metastasis and prostate cancer specific mortality across multiple risk groups and treatment strategies, based on 14 studies with data from more than 8,000 patients (source: Clinical Genitourinary Cancer publication).Recent updates
Seeking Alpha • 6h
Myriad Genetics: Strong Oncology Demand, But Monetization Breaks Down
Summary Myriad Genetics faces persistent reimbursement and pricing headwinds, despite stable oncology volumes and pipeline momentum, driving margin compression and revenue volatility. Management is executing the Ascend initiative, aiming to optimize the revenue cycle, automate claims, and improve payer engagement, with the potential for margin inflection by 2027 if successful. FY26 revenue guidance is tightened to $770–$790 million, with adjusted EBITDA guidance withdrawn, reflecting near-term uncertainty and limited visibility on operational improvements. I maintain a Hold rating, as the business remains a turnaround story; execution on reimbursement and revenue conversion is critical before upside can be realized. Read the full article on Seeking AlphaMise à jour du récit • Jul 09
MYGN: New Cancer Test Data And AI Initiatives Will Support A Balanced Outlook
Analysts trimmed their price outlook for Myriad Genetics, lowering the implied fair value estimate from $8.12 to $6.25 as they recalibrated assumptions around revenue growth, profit margins, and future P/E expectations following recent research updates. What’s in the News for Myriad Genetics Myriad Genetics reported new large scale meta analysis data for its Prolaris Biopsy Test in localized prostate cancer, showing that the combined clinical risk score was significantly prognostic for distant metastasis and prostate cancer specific mortality across multiple risk groups and treatment strategies, based on 14 studies with data from more than 8,000 patients (source: Clinical Genitourinary Cancer publication).
Mise à jour du récit • Jun 25
MYGN: 2026 Turnaround Will Be Driven By Expanded Cancer Testing Reach
Analysts have trimmed their target on Myriad Genetics stock by $1, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What’s in the News for Myriad Genetics Expanded availability of the Precise MRD test to patients with breast, colorectal, and renal cancers in the U.S., targeting a population of more than 6 million individuals and providing personalized, whole genome sequencing based ctDNA monitoring across the cancer care continuum.
Mise à jour du récit • Jun 08
MYGN: 2026 Revenue Outlook And Lowered Multiple Will Pressure Sentiment
Analysts have modestly reduced their price target on Myriad Genetics by $1, citing updated assumptions around revenue growth, profitability and future P/E multiples reflected in recent research, including the TD Cowen report. What's in the News Myriad plans to present extensive data on its Precise MRD test across multiple solid tumor types, including interim outcomes from the MONSTAR-SCREEN-3 study.Mise à jour du récit • May 25
MYGN: 2026 Turnaround Execution And Cancer Testing Expansion Will Drive Upside
The analyst price target for Myriad Genetics has been reset from $16.06 to $10.00 as analysts factor in lower Street targets around $6, updated assumptions for revenue growth and profit margins, and a revised future P/E closer to 6.3x. Analyst Commentary Recent Street research has generally moved toward more cautious price targets around US$6, but there are still some constructive signals that matter if you are looking at Myriad Genetics through a valuation and execution lens.Mise à jour du récit • Apr 21
MYGN: 2026 Turnaround And Pipeline Milestones Will Keep Sentiment Cautious
Analyst price targets on Myriad Genetics have moved slightly lower, with recent cuts to $6 from $8 and $6.50, as analysts wait for clearer evidence of progress on the turnaround plan, pipeline milestones, and improved growth and profitability before shifting their stance. Analyst Commentary Recent Street research reflects a cautious stance on Myriad Genetics, with bearish analysts trimming price targets and highlighting execution and growth risks despite some operational positives.Mise à jour du récit • Apr 05
MYGN: 2026 Turnaround Execution And Pipeline Delivery Will Sustain Bearish Caution
Analysts have trimmed their price targets on Myriad Genetics to a range of $6 to $7, reflecting caution around the pace of the turnaround and the need for clearer progress on growth, profitability and pipeline execution before taking a more constructive stance. Analyst Commentary Recent research updates point to a cautious tone, with several bearish analysts trimming price targets into the US$6 to US$7 range and maintaining neutral ratings.Mise à jour du récit • Mar 21
MYGN: Turnaround Execution In 2026 Will Drive Continued Cautious Sentiment
The Street’s blended price target for Myriad Genetics has shifted lower into a $6 to $7 range as analysts factor in updated sector models, reiterated 2026 guidance, and the need for clearer progress on the company’s turnaround and profitability before becoming more constructive. Analyst Commentary Recent research updates show a clear tilt toward caution, with several bearish analysts trimming their valuation ranges for Myriad Genetics and keeping ratings in the middle of the scale rather than moving to a more positive stance.Mise à jour du récit • Mar 06
MYGN: Turnaround Execution And 2026 Pipeline Milestones Will Drive Bearish Outlook
Analysts have trimmed their price targets on Myriad Genetics to a range of about $6 to $7, reflecting more cautious assumptions on growth and profitability even as they acknowledge recent results and the company’s ongoing turnaround efforts. Analyst Commentary Recent research updates show bearish analysts trimming price targets on Myriad Genetics into a tighter band around $6 to $7, signaling a more cautious stance on the stock even as they acknowledge operational progress.Mise à jour du récit • Feb 19
MYGN: Rebased Outlook Weighs Execution Risks Against Upcoming MRD Commercialization Potential
Analysts have adjusted their outlook on Myriad Genetics, trimming the average price target to $7 from $9. They have also updated their assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E based on recent diagnostics sector research and expectations for solid results and 2026 guidance.Article d’analyse • Feb 13
Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding
To the annoyance of some shareholders, Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares are down a considerable 27% in the...Mise à jour du récit • Feb 05
MYGN: Sector Fundamentals And New Diagnostics Partnerships Will Support A More Constructive Outlook
Analysts have lowered their price target on Myriad Genetics to $7 from $9, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, while still expecting solid diagnostics sector results and 2026 outlooks. Analyst Commentary Recent research on Myriad Genetics focuses on how the updated $7 price target lines up with expectations for the broader diagnostics group, where analysts still see solid sector results and 2026 outlooks supported by what they describe as strong fundamentals.Article d’analyse • Feb 04
Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Mise à jour du récit • Jan 22
MYGN: Sector Strength And Expanded Cancer Testing Will Support Future Upside
Narrative Update Analysts have adjusted their view on Myriad Genetics, reflected in a higher fair value estimate from $14.33 to $16.06 as they weigh mixed price target moves in recent research and slightly different assumptions for growth, margins, and future P/E. Analyst Commentary Recent Street research on Myriad Genetics presents a mixed but informative picture, with some caution on price targets alongside more constructive adjustments that support the updated fair value estimate.Mise à jour du récit • Jan 08
MYGN: Sector Strength And New Partnerships Will Support A More Constructive Outlook
Narrative Update The analyst price target for Myriad Genetics has shifted modestly lower, with a blended change of roughly $1 across recent moves to $7 and $8. Analysts are factoring in updated diagnostics sector expectations and revising their fair value estimates and P/E outlooks for the company.Mise à jour du récit • Dec 24
MYGN: Rising Margin Visibility Will Support A More Constructive Bullish Outlook
Analysts have raised their price target on Myriad Genetics shares from $6.00 to $8.00, reflecting modest improvements in long term profit margin expectations and valuation assumptions, while maintaining a neutral overall outlook. Analyst Commentary Analyst commentary around the revised price target highlights a generally balanced view, with recognition of incremental progress offset by lingering execution and profitability concerns.Mise à jour du récit • Dec 10
MYGN: Improved Earnings Visibility Will Shape Bullish Outlook
Analysts have modestly raised their price target on Myriad Genetics to $8 from $6, reflecting a slightly higher fair value estimate supported by improved forward price to earnings assumptions and a marginally higher discount rate that still preserves cautious revenue growth expectations. Analyst Commentary Analyst sentiment around Myriad Genetics remains balanced, with the higher price target reflecting modest improvements in forward expectations rather than a decisive shift in outlook.Mise à jour du récit • Nov 26
MYGN: Breast Cancer Risk Collaboration And Margin Gains Will Shape Outlook
Narrative Update on Myriad Genetics Analysts have raised their price target for Myriad Genetics from $6 to $8, citing improved profit margins and modest revenue growth as key drivers for the upward revision. Analyst Commentary Analyst opinions about Myriad Genetics reflect a mix of optimism regarding the company's recent performance and continued caution around potential challenges.Mise à jour du récit • Nov 12
MYGN: Expanded Cancer Testing Is Expected To Drive Future Gains
Narrative Update on Myriad Genetics Analysts have increased their price target for Myriad Genetics from $6 to $8. This adjustment reflects revised expectations based on updates to fair value assessments, discount rates, and future earnings metrics.Mise à jour du récit • Oct 29
Adding Cancer Test Capabilities And Mental Health Data Will Support Long-Term Progress
Analysts have slightly raised their price target for Myriad Genetics to approximately $7.95 from $7.77 per share. They cited modest improvements in expected profit margins and updated assumptions around discount rates.Mise à jour du récit • Oct 14
Expanding Oncology Testing And Genomic Profiling Will Widen Market Reach
Analysts have adjusted their price target for Myriad Genetics upward from $7.38 to $7.77, citing minor improvements in profit margin and future price-to-earnings expectations, even though revenue growth projections have been slightly reduced. What's in the News Myriad Genetics has formed a strategic partnership with SOPHiA GENETICS to develop and globally deploy a liquid biopsy companion diagnostic test for pharmaceutical companies, leveraging both companies' expertise and international networks (Strategic Alliances).Article d’analyse • Sep 30
Estimating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)
Key Insights Myriad Genetics' estimated fair value is US$8.13 based on 2 Stage Free Cash Flow to Equity Myriad...Article d’analyse • Aug 17
Myriad Genetics, Inc. (NASDAQ:MYGN) Held Back By Insufficient Growth Even After Shares Climb 28%
NasdaqGS:MYGN 1 Year Share Price vs Fair Value Explore Myriad Genetics's Fair Values from the Community and select...Article d’analyse • Jun 25
Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Those holding Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares would be relieved that the share price has rebounded 29% in...Article d’analyse • May 09
Lacklustre Performance Is Driving Myriad Genetics, Inc.'s (NASDAQ:MYGN) 48% Price Drop
To the annoyance of some shareholders, Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares are down a considerable 48% in the...
Nouveau récit • Mar 24
PATHOMIQ AI Partnership Will Expand Oncology And Women's Health
Strategic partnerships and investments in AI and women's health aim to enhance oncology offerings and capture larger market shares, driving revenue growth.Article d’analyse • Mar 16
Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31%
Myriad Genetics, Inc. ( NASDAQ:MYGN ) shareholders that were waiting for something to happen have been dealt a blow...Article d’analyse • Feb 26
Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results
There's been a notable change in appetite for Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares in the week since its annual...Rendement pour les actionnaires
| MYGN | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | -49.0% | -0.7% | 0.8% |
| 1Y | -26.9% | 31.1% | 19.1% |
Rendement vs Industrie: MYGN a sous-performé le secteur US Biotechs qui a rapporté 31.1 % au cours de l'année écoulée.
Rendement vs marché: MYGN a sous-performé le marché US qui a rapporté 19.1 % au cours de l'année écoulée.
Volatilité des prix
| MYGN volatility | |
|---|---|
| MYGN Average Weekly Movement | 16.9% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: Le cours de l'action de MYGN a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de MYGN ( 17% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1991 | 2,700 | Sam Raha | www.myriad.com |
Myriad Genetics, Inc. est une entreprise de diagnostic moléculaire et de médecine de précision qui développe des tests moléculaires. La société propose des tests de diagnostic moléculaire pour l'oncologie, la santé des femmes et la pharmacogénomique. Elle propose également le test MyRisk Hereditary Cancer, un test de séquençage de l'ADN pour les cancers héréditaires ; le test BRACAnalysis CDx Germline Companion Diagnostic, un test de séquençage de l'ADN pour les cancers métastatiques du sein, de l'ovaire, du pancréas et de la prostate présentant des variantes BRCA germinales délétères ou suspectées de l'être ; et le test MyChoice CDx Companion Diagnostic, un test tumoral qui détermine le statut de déficit de recombinaison homologue chez les patientes atteintes d'un cancer de l'ovaire.
Myriad Genetics, Inc. Résumé des fondamentaux
| MYGN statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$513.37m |
| Bénéfices(TTM) | -US$399.90m |
| Recettes(TTM) | US$829.00m |
0.3x
Ratio P/S-0.7x
Ratio P/ELe site MYGN est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| MYGN compte de résultat (TTM) | |
|---|---|
| Recettes | US$0 |
| Coût des recettes | US$0 |
| Marge brute | US$0 |
| Autres dépenses | US$0 |
| Les revenus | US$0 |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -4.18 |
| Marge brute | 69.96% |
| Marge bénéficiaire nette | -48.24% |
| Ratio dettes/capitaux propres | 35.7% |
Quelles ont été les performances à long terme de MYGN?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/31 15:28 |
| Cours de l'action en fin de journée | 2026/07/31 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Myriad Genetics, Inc. est couverte par 36 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jack Meehan | Barclays |
| Derek Taller | Benchmark Company |
| Michael Ryskin | BofA Global Research |